The cell culture market is estimated to be valued at USD 22.56 BN in 2024 and grow at a CAGR of 11.8% over the forecast period (2024 – 2031). Advancements in cell-based research for developing new cell lines are supporting the market growth. Furthermore, the rising demand for cell-based vaccines, recombinant proteins, and monoclonal antibodies is fueling the demand for cell culture products.
Market Dynamics:
The growth of the global cell culture market is driven largely by two key factors. Firstly, increasing R&D investments by pharmaceutical and biotechnology companies in drug discovery and development are contributing significantly to the demand for cell culture products. Cell-based assays have become essential during preclinical testing to analyze drug toxicity and efficacy. Secondly, the current COVID-19 pandemic has underscored the need for rapid development of vaccines and therapeutics. This is propelling research activities in cell-based vaccine production using vero and MDCK cell lines. As a result, players in the market are experiencing heightened demand for cell culture media, reagents, and equipment required for vaccine manufacturing processes.
Increasing Demand for Monoclonal Antibodies
The production of monoclonal antibodies has been one of the major application areas of cell culture technology. Monoclonal antibodies find extensive applications in disease diagnosis and treatment. They are increasingly being used for treatment of various conditions like cancer, arthritis, cardiovascular diseases, etc. The rising prevalence of such diseases and increasing approvals for monoclonal antibody therapies is expected to drive the demand for cell culture technology in the production of such therapeutic proteins.
Advancements in Regenerative Medicine and Tissue Engineering
Regenerative medicine aims to regenerate, repair, or replace damaged cells, tissues or organs. Cell culture plays a vital role in regenerative medicine research as it allows production of large quantities of cells required for various applications. Advancements in stem cell research, development of 3D culture systems and scaffold-based techniques are expanding the applications of cell culture in regenerative medicine and tissue engineering. This is anticipated to boost the cell culture market in the coming years.
High Capital Investments Required
Establishing cell culture facilities involves high capital investments for setting up infrastructure like bioreactors, cell culture vessels, storage facilities, monitoring and control equipment, etc. Operation and maintenance of such facilities also incurs considerable running costs. This high initial setup and operating costs can restrain small companies and research organizations from entering the cell culture market.
Complex Regulatory Framework
Cell culture products are extensively regulated by various regulatory bodies like FDA in the U.S. and European Medicines Agency (EMA) in Europe. Stringent regulations are in place to ensure product safety, efficacy, and quality. Navigating the complex regulatory landscape for approval and licensure of new cell culture products can delay their market launch. Regulatory compliance also increases the overall costs. The complicated regulatory framework thus acts as a challenge for smooth growth of the cell culture market.
Increasing Outsourcing of Cell Culture Services
With advances in cell culture techniques, several new biologics and cell/gene therapies are being developed. However, most biotech and pharmaceutical companies lack in-house capabilities for manufacturing activities. This encourages the outsourcing of cell culture development and the manufacturing to specialized contract service providers. The outsourcing trend presents lucrative opportunities for contract development and manufacturing organizations in the cell culture market.
Emerging Economies in Asia Pacific
Countries like China, India, South Korea, and others in Asia Pacific are witnessing tremendous economic growth. These emerging countries are increasingly investing in the biopharmaceutical and life sciences sectors. The presence of low-cost skilled workforce and focus on establishing world-class research infrastructure makes Asia Pacific an attractive investment destination. This provides significant opportunities for global as well as local players in the cell culture market to expand their geographic footprint.
Link: https://www.coherentmarketinsights.com/market-insight/cell-culture-market-116
Key Development
- On February 7, 2024, 10x Genomics, Inc., a leader in single-cell and spatial biology solutions, has introduced GEM-X, the latest iteration of its renowned single-cell technology. Serving as a significant advancement within the chromium framework since the introduction of Next GEM technology in 2019, GEM-X is built upon an innovative microfluidic chip design. It integrates state-of-the-art technological enhancements and refined reagents, ensuring unparalleled performance and robust reliability.
- On January 24, 2024, Merck & Co., Inc., a leading science and technology company, has disclosed that its Life Science division has initiated a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech, a specialized Contract Development and Manufacturing Organization (CDMO) focusing on biologics. The primary objective of this agreement is to explore potential collaboration avenues for introducing innovative and scalable bioprocessing solutions to Taiwan as well as various global markets.
- In September 2023, PhenomeX Inc., a renowned entity specializing in functional cell biology, has announced that GSK plc, a prominent biopharmaceutical company, will present findings on the SpotLight Human Lambda reagent for the Beacon platform at the forthcoming 16th annual Conference on Protein Expression in Animal Cells. The conference is slated to be held in Sitges, Spain, from September 24-28, 2023.
- In January 2023, Curate Biosciences, a key player in the life sciences domain, has unveiled its revolutionary Curate Cell Processing System. Serving as a trailblazer in its field, the Curate System delivers high-quality starting materials essential for CAR-T cancer therapy and other cell-based treatments. By employing an exceptionally precise microfluidic approach, it achieves an impressive approximately 90% recovery of white blood cells while effectively eliminating over 90% of red cells and 99% of platelets from leukapheresis blood products sourced from patients.
Key Players: Merck KGaA, Sartorius AG, BioSpherix, Ltd., Cell Culture Company, LLC, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickson and Company, Evonik, Promocell GmbH, Hi-Media Laboratories, Sekisui XenoTech LLC, Lonza Group, Agilent Technologies Inc., Cytiva, 300MICRONS GmbH, PL BioScience GmbH, and denovoMATRIX GmbH
